Abstract: The invention relates to a process for producing an aqueous gel comprising hyaluronic acid, vitamin C, and a stabilizing agent selected from the metabisulfites. According to the invention, such a process comprises the steps of a) preparing a mixture comprising crosslinked or non-crosslinked hyaluronic acid and/or a salt thereof with a molar mass of between 1000 Da and 10 MDa, from 0.1 to 20.0% by weight of vitamin C in its acid form, or its equivalent in ascorbate derived from a vitamin C salt, from 0.01 to 1.00% by weight of a stabilizing agent selected from the metabisulfites, and an aqueous solution added so that the hyaluronic acid content is between 0.01 and 100 mg/ml, so as to form a hydrogel, and b) degassing the mixture before the hydrogel being formed is completely swollen.

Abstract: The invention relates to a process for producing an aqueous gel comprising hyaluronic acid, vitamin C, and a stabilizing agent selected from the metabisulfites. According to the invention, such a process comprises the steps of a) preparing a mixture comprising crosslinked or non-crosslinked hyaluronic acid and/or a salt thereof with a molar mass of between 1000 Da and 10 MDa, from 0.1 to 20.0% by weight of vitamin C in its acid form, or its equivalent in ascorbate derived from a vitamin C salt, from 0.01 to 1.00% by weight of a stabilizing agent selected from the metabisulfites, and an aqueous solution added so that the hyaluronic acid content is between 0.01 and 100 mg/ml, so as to form a hydrogel, and b) degassing the mixture before the hydrogel being formed is completely swollen.

Abstract: A stable galenic composition of a compound of general formula (I) wherein R1 and R2 both represent independently of each other an alkyl, aryl, arylalkyl group, optionally substituted with one or more linear or branched groups, optionally bearing one or more heteroatoms, comprising said compound of formula I in an amount ranging from 0.01 to 15% by weight based on the total weight of the final composition; at least one anhydrous ester, the main chain and/or optionally the branched chains of which are free from free and/or reactive groups or functions, in an amount ranging from 0.1 to 99.9% by weight based on the total weight of the cosmetically and pharmaceutically acceptable composition; and optionally a cosmetically and pharmaceutically acceptable excipient for completing the 100% of the total weight of the composition.

Abstract: A method for synthesizing an isothiocyanate of general formula (I) SCN—R1—R4—R2??(I) wherein R1 and R2 represent independently of each other an alkyl-aryl or aryl group, R4 represents a carbonyl, sulfinyl, sulfonyl group or a sulfide group and of its derivatives comprising a step for reacting an alkylalkylamine having the general formula (II) NH2—R1—R4—R2??(II) wherein R1 and R2 represent independently of each other an alkyl, aryl or alkylaryl group, R4 represents a carbonyl, sulfinyl, sulfonyl or sulfide group, in the presence of carbon sulfide and of di-tert-butyl dicarbonate with formation of the corresponding aforesaid isothiocyanate, compounds obtained by this method as well as their uses.

Abstract: A stable galenic composition of a compound of general formula (I) wherein R1 and R2 both represent independently of each other an alkyl, aryl, arylalkyl group, optionally substituted with one or more linear or branched groups, optionally bearing one or more heteroatoms, comprising said compound of formula I in an amount ranging from 0.01 to 15% by weight based on the total weight of the final composition; at least one anhydrous ester, the main chain and/or optionally the branched chains of which are free from free and/or reactive groups or functions, in an amount ranging from 0.1 to 99.9% by weight based on the total weight of the cosmetically and pharmaceutically acceptable composition; and optionally a cosmetically and pharmaceutically acceptable excipient for completing the 100% of the total weight of the composition.

Abstract: The present invention is related to the use of a composition having an adequate pharmaceutical or cosmetic carrier or diluent and a sufficient amount of vitamin K1 oxide or its derivative for the treatment and/or the prevention of mammal dermatological lesions. The present invention is also related to a cosmetic composition having an adequate cosmetic carrier, phospholipids and vitamin K1 oxide or its derivative.

Abstract: A cosmetic or pharmaceutical composition includes particles of hyaluronic acid having a molecular weight between 20000 Da and 3000000 Da, combined with a polyamine.

Abstract: Use, method of manufacturing a pharmaceutical composition, pharmaceutical composition for the treatment of skin ailments comprising a therapeutic quantity in aqueous solution of nitric acid of 5 to 15 mmol/ml of pharmaceutical composition, and also comprising a zinc salt at a concentration of 0.01 to 0.015 mg of Zn2+ ions/ml as well as a copper salt at a concentration of 0.01 to 0.015 mg of Cu2+ ions/ml of pharmaceutical composition and its medical device.

Abstract: The present invention is related to the use of a composition having an adequate pharmaceutical or cosmetic carrier or diluent and a sufficient amount of vitamin K1 oxide or its derivative for the treatment and/or the prevention of mammal dermatological lesions. The present invention is also related to a cosmetic composition having an adequate cosmetic carrier, phospholipids and vitamin K1 oxide or its derivative.

Abstract: This invention relates to skin treatments containing nano-sized vitamin K. Specifically, the invention relates to a skin treatment containing nano-sized vitamin K for the use in improving the aesthetic aspects of the skin.